CMV viremia and disease
| Subgroup . | Serology . | CMV viremia . | P3-150 . | CMV disease . | |||||
|---|---|---|---|---|---|---|---|---|---|
| Donor . | Recipient . | Prophylactic granulocyte transfusions: cohort A . | No prophylactic granulocyte transfusions: cohort B . | Prophylactic granulocyte transfusions: cohort A . | No prophylactic granulocyte transfusions: cohort B . | ||||
| Proportion (%) . | Proportion (%) . | Proportion (%) . | (95% CI) . | Proportion (%) . | (95% CI) . | ||||
| 1 | + | + | 11/27 (40.7) | 31/59 (52.5) | .36 | 3/27 (11.1) | (2.4%, 29.2%) | 1/59 (1.7) | (0.04%, 9.1%) |
| 2 | + | − | 5/15 (33.3) | 8/26 (30.8) | .99 | 2/15 (13.3) | (1.7%, 40.5%) | 1/26 (3.8) | (0.1%, 19.6%) |
| 3 | − | + | 8/17 (47.1) | 8/20 (40) | .75 | 1/17 (5.9) | (0.15%, 28.7%) | 3/20 (15.0) | (3.2%, 37.9%) |
| 4 | − | − | 1/24 (4.2) | 1/37 (2.7) | .99 | 0/24 (0.0) | (0.0%, 11.7%) | 0/37 (0.0) | (0.0%, 10.5%) |
| Subgroup . | Serology . | CMV viremia . | P3-150 . | CMV disease . | |||||
|---|---|---|---|---|---|---|---|---|---|
| Donor . | Recipient . | Prophylactic granulocyte transfusions: cohort A . | No prophylactic granulocyte transfusions: cohort B . | Prophylactic granulocyte transfusions: cohort A . | No prophylactic granulocyte transfusions: cohort B . | ||||
| Proportion (%) . | Proportion (%) . | Proportion (%) . | (95% CI) . | Proportion (%) . | (95% CI) . | ||||
| 1 | + | + | 11/27 (40.7) | 31/59 (52.5) | .36 | 3/27 (11.1) | (2.4%, 29.2%) | 1/59 (1.7) | (0.04%, 9.1%) |
| 2 | + | − | 5/15 (33.3) | 8/26 (30.8) | .99 | 2/15 (13.3) | (1.7%, 40.5%) | 1/26 (3.8) | (0.1%, 19.6%) |
| 3 | − | + | 8/17 (47.1) | 8/20 (40) | .75 | 1/17 (5.9) | (0.15%, 28.7%) | 3/20 (15.0) | (3.2%, 37.9%) |
| 4 | − | − | 1/24 (4.2) | 1/37 (2.7) | .99 | 0/24 (0.0) | (0.0%, 11.7%) | 0/37 (0.0) | (0.0%, 10.5%) |
Fisher exact test.